Tirzepatide is a dual hormone receptor agonist that simultaneously activates the GIP and GLP-1 receptors, two of the body’s key metabolic signalling pathways. By engaging both receptors together, it supports improved insulin sensitivity, more stable blood glucose regulation, and enhanced satiety signalling. This dual-pathway mechanism sets it apart from single-receptor compounds, offering a more comprehensive approach to metabolic support and appetite regulation.
